In This Issue, Volume 4, Issue 8

Abstract

Type 2 diabetes is the most common form of diabetes, wherein the body develops insulin resistance or reduced insulin production, resulting in high blood glucose. Insulin secretagogues are used for effective control of insulin production in patients. However, some agents are associated with the risk of hypoglycemia as they trigger insulin release independently of the level of blood glucose. Therefore, novel glucose-dependent insulin secretagogues are highly desired for the treatment of diabetes.Here, Toda et al.

Transformation of Rheumatoid Arthritis to Adult Still’s Disease

“…After two days of therapy with dexamethasone 16 mg/day IV the patient was still febrile (40°C) and confused. Because patient's history of recurrent severe bacteremia, along with supportive literature about the efficacy of IVIG in refractory cases of AOSD [2,3] and our experience showing only very high dose of corticosteroid therapy may be helpful for aggressive AOSD, we decided to start dexamethasone 16 mg×3/day IV along with intravenous immunoglobulines 25 g/day for 5 days. Of note, IG level before therapy was within normal range with mildly elevated IGA (428 mg/dl, N=70-350).…”